Diabetes

Insulin LY2605541 tops glargine for glycemic control in T1DM

(HealthDay)—For patients with type 1 diabetes, the novel, long-acting basal insulin LY2605541 yields greater improvement in glycemic control compared with insulin glargine, according to a study published online Nov. 27 ...

Diabetes

Insulin glargine's main metabolic effect as metabolite M1

(HealthDay)—For patients with type 2 diabetes, following administration of a subcutaneous injection of a therapeutic dose of insulin glargine, glargine is minimally detectable in blood, and most of the plasma insulin concentration ...

Diabetes

Insulin glargine 300 safe, effective in seniors with T2DM

(HealthDay)—For older adults, insulin glargine 300 units/mL (Gla-300) is safe and as effective as Gla-100, with a similarly low or lower risk of symptomatic hypoglycemia, according to a study published online June 12 in ...

Diabetes

ADA: degludec noninferior for cardiovascular events in T2DM

(HealthDay)—Among high-risk patients with type 2 diabetes, degludec is noninferior to glargine in terms of the incidence of cardiovascular events, according to a study published online June 12 in the New England Journal ...

Diabetes

Insulin glargine 300 U/mL beats glargine 100 U/mL in T1DM

(HealthDay)—For patients with type 1 diabetes, receipt of insulin glargine 300 U/mL (Gla-300) is associated with better glucose control than glargine 100 U/mL (Gla-100), regardless of injection time, according to a study ...

page 2 from 3